Recent Updates
Recently added Catalysts
RZLT Positive Sentiment Score: 75/100

Rezolute Reports First Quarter Fiscal 2024 Results Redwood City, Calif.

Key Takeaway: Rezolute, Inc. reported its financial results for the first quarter of fiscal 2024, highlighting significant developments in its clinical programs. The company has received PRIME eligibility from the European Medicines Agency for RZ358, poised to begin a Phase 3 study targeting congenital hyperinsulinism. Concurrently, enrollment is nearing completion for the Phase 2 study of RZ402 aimed at diabetic macular edema, with results expected before year-end. However, the results also show an increased net loss and rising operating expenses compared to the previous year.

Market Sentiment Analysis

POSITIVE FACTORS

  • Rezolute has achieved PRIME eligibility from the European Medicines Agency for RZ358.
  • The company plans to initiate a pivotal Phase 3 clinical study for RZ358 to treat congenital hyperinsulinism.
  • Enrollment for the Phase 2 study of RZ402 for diabetic macular edema is expected to be completed this quarter.

CONCERNS & RISKS

  • The net loss for the first quarter of fiscal 2024 increased to $14.524 million from $9.831 million year-over-year.
  • Operating expenses rose significantly from $10.218 million to $15.914 million.

Full Press Release Details

Rezolute Reports First Quarter Fiscal 2024
Redwood City, Calif.,
November 13, 2023 -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing
novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter
of fiscal 2024 ended September 30, 2023.
to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained
PRIME eligibility from the European Medicines Agency for this indication," said Nevan Charles Elam, Chief Executive Officer and
Founder of Rezolute. "We also anticipate completing enrollment this quarter for our ongoing Phase 2 study of RZ402 for the treatment
of diabetic macular edema and plan to provide an update on the study prior to year end."
o Received EMA priority medicines (PRIME) designation for the treatment of congenital hyperinsulinism (cHI) from the European Medicines Agency
o Plan to initiate sunRIZE, a pivotal Phase 3 clinical study in patients with cHI, in Europe and other geographies outside the US in the fourth quarter 2023
o Continuing the administration of RZ358 in the US with FDA approval under a compassionate use program to treat patients with tumor associated hyperinsulinism, including for a patient with refractory hypoglycemia due to metastatic insulinoma who has remained on RZ358 for nearly a year
o Multi-center, randomized, double-masked, placebo-controlled, parallel-arm study ongoing to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are na ve to or have received limited anti-VEGF injections
o Study is in the latter stages of patient recruitment and an update on the study will be provided prior to year end
First Quarter Fiscal
2024 Financial Results
Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating
rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment
burden for patients, treating physicians, and the healthcare system. Rezolute is steadfast in its mission to create profound, positive,
and lasting impacts on patients' lives. Patient, clinician, and advocate voices are integrated in the Company's drug development
process. Rezolute places an emphasis on understanding the patient's lived experiences, enabling the Company to boldly address a
range of severe conditions. For more information, visit www.rezolutebio.com.
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain
certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the
Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to
be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of
1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain
assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "project," "seek,"
"strive," "try," or future or conditional verbs such as "could," "may," "should," "will,"
"would," or similar expressions. These forward-looking statements include, but are not limited
to and statements regarding PRIME designation and the designation's meaning on the ability of RZ358 to become an effective treatment
to congenital HI, the effectiveness or future effectiveness of RZ358 for the treatment of congenital HI, and statements regarding clinical
trial timelines for RZ358. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly,
actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes
no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements
were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including
the Risk Factors contained in the Rezolute's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are
available at the SEC's website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking
statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their
entirety by this cautionary statement.
Stephanie Carrington
Condensed Consolidated Financial Statements Data
(in thousands, except per share data)
Three Months Ended
September 30,
2023 2022
Condensed Consolidated Statements of Operations Data:
Operating expenses:
Research and development $ 12,214 $ 7,704
General and administrative 3,700 2,514
Total operating expenses 15,914 10,218
Loss from operations (15,914 ) (10,218 )
Non-operating income (expense), net 1,390 387
Net loss $ (14,524 ) $ (9,831 )
Basic and diluted net loss per common share $ (0.28 ) $ (0.19 )
Shares used to compute basic and diluted net loss per common share 51,409 50,528
September 30, June 30,
2023 2023
Condensed Consolidated Balance Sheets Data:
Cash and cash equivalents $ 8,057 $ 16,036
Investments in marketable debt securities 98,817 102,330
Working capital 95,450 99,710
Total assets 112,999 123,721
Accumulated deficit (275,509 ) (260,985 )
Total stockholders' equity 103,564 116,172

Frequently Asked Questions

What recent achievement did Rezolute secure for RZ358?

Rezolute received PRIME eligibility from the EMA for RZ358 to treat congenital hyperinsulinism.

What study is Rezolute planning to start for RZ358?

Rezolute plans to initiate the pivotal Phase 3 sunRIZE study in patients with congenital hyperinsulinism.

What is the focus of Rezolute's Phase 2 study?

The ongoing Phase 2 study evaluates RZ402 for treating diabetic macular edema.

What was Rezolute's net loss for Q1 2024?

Rezolute reported a net loss of $14,524,000 for the first quarter of fiscal 2024.

How much cash does Rezolute have as of September 2023?

As of September 2023, Rezolute has $8,057,000 in cash and cash equivalents.

Last updated: Nov 13, 2023